UKCCCR trial to study the effect on breast cancer mortality of annual mammographic screening starting at age 40

Conditions

Breast cancer Cancer Breast cancer

Stephen W. Duffy, Daniel Vulkan, Howard Cuckle, Dharmishta Parmar, Shama Sheikh et al. (14 authors)

Health Technology Assessment2020-10-0183 citations

Effect of mammographic screening from age 40 years on breast cancer mortality (UK Age trial): final results of a randomised, controlled trial.

Duffy SW, Vulkan D, Cuckle H, Parmar D, Sheikh S, Smith RA, Evans A, Blyuss O, Johns L, Ellis IO, Myles J, Sasieni PD, Moss SM.

2020-08-12147 citations

10.1016/s1470-2045(20)30398-3

Assessing within-woman changes in mammographic density: a comparison of fully versus semi-automated area-based approaches.

Busana MC, De Stavola BL, Sovio U, Li J, Moss S, Humphreys K, dos-Santos-Silva I.

2016-02-0412 citations

10.1007/s10552-016-0722-9

Effect of mammographic screening from age 40 years on breast cancer mortality in the UK Age trial at 17 years' follow-up: a randomised controlled trial.

Moss SM, Wale C, Smith R, Evans A, Cuckle H, Duffy SW.

2015-07-20132 citations

10.1016/s1470-2045(15)00128-x

Randomized controlled trial of mammographic screening from age 40 ('Age' trial): patterns of screening attendance.

Johns LE, Moss SM, Trial Management Group.

2010-01-0115 citations

10.1258/jms.2010.009091

Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years' follow-up: a randomised controlled trial.

Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, Trial Management Group.

2006-12-01287 citations

10.1016/s0140-6736(06)69834-6

Interventions

Women in the intervention group are offered annual screening by mammography until the year of their 48th birthday. Screening is by 2-view mammography at 1st screen and single view subsequently. All

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Women aged 40-41 identified from Health Authorities registers

Exclusion criteria

Exclusion criteria: Women under care for breast cancer may be removed from the prior notification list by the GPs prior to randomisation

Design outcomes

Primary

Measure	Time frame
Deaths from breast cancer in women free of the disease at trial entry in the two groups. Information on prognostic factors of all breast cancers is also collected.	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed